BioNexus Gene Lab Corp: Form 10-Q for the period ended Jun 30, 2023
Filed with the SEC on Aug 16, 2023 and accepted by EDGAR at Aug 16, 2023, 15:26 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-04-01 to 2023-06-30 | $2.6m | us-gaap:Revenues |
| Revenue | 6 months2023-01-01 to 2023-06-30 | $4.9m | us-gaap:Revenues |
| Cost of revenue | 3 months2023-04-01 to 2023-06-30 | $2.2m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2023-01-01 to 2023-06-30 | $4.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2023-04-01 to 2023-06-30 | $339.7k | us-gaap:GrossProfit |
| Gross profit | 6 months2023-01-01 to 2023-06-30 | $708.6k | us-gaap:GrossProfit |
| Operating income | 3 months2023-04-01 to 2023-06-30 | −$272.2k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-01-01 to 2023-06-30 | −$322.8k | us-gaap:OperatingIncomeLoss |
| Interest expense | 6 months2023-01-01 to 2023-06-30 | $5.5k | us-gaap:InterestExpense |
| Net income | 3 months2023-04-01 to 2023-06-30 | −$259.3k | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-01-01 to 2023-06-30 | −$328.3k | us-gaap:NetIncomeLoss |
| Operating cash flow | 6 months2023-01-01 to 2023-06-30 | −$140.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-01-01 to 2023-06-30 | $14.5k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2023-06-30 | $297.1k | us-gaap:Cash |
| Current assets | At period end2023-06-30 | $5.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-06-30 | $7.9m | us-gaap:Assets |
| Current liabilities | At period end2023-06-30 | $1.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-06-30 | $1.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2023-06-30 | $6.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001477932-23-006208. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.